Julia Tchou, MD, PhD, on Clinical Implications of Combining a Radiation Boost and Pembrolizumab in Triple-Negative Breast Cancer

Posted: Friday, December 2, 2022

Julia Tchou, MD, PhD, of the University of Pennsylvania, discusses results of the phase Ib/II BreastVax study, which suggested that combining radiotherapy with immune checkpoint inhibition in the form of a single neoadjuvant dose of pembrolizumab may result in pathologic response in patients with early-stage triple-negative breast cancer. This approach may help select patients as candidates for chemotherapy omission.